Get the Stockscreener App
135.78
7.13%
9.04
Illumina Inc stock is traded at $135.78, with a volume of 2.77M.
It is up +7.13% in the last 24 hours and up +7.23% over the past month.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
See More
Previous Close:
$126.74
Open:
$133.22
24h Volume:
2.77M
Relative Volume:
1.49
Market Cap:
$20.63B
Revenue:
$4.34B
Net Income/Loss:
$850.00M
P/E Ratio:
24.85
EPS:
5.4635
Net Cash Flow:
$921.00M
1W Performance:
+6.18%
1M Performance:
+7.23%
6M Performance:
+9.91%
1Y Performance:
+77.47%
1-Day Range:
$128.06
$136.63
1-Week Range:
$119.14
$136.63
52-Week Range:
$73.86
$155.53
Illumina Inc Stock (ILMN) Company Profile
Name
Illumina Inc
Sector
Industry
Phone
(858) 202-4500
Address
5200 ILLUMINA WAY, SAN DIEGO, CA
Compare ILMN vs TMO, DHR, IDXX, A, WAT
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ILMN
Illumina Inc
|
135.78 | 20.63B | 4.34B | 850.00M | 921.00M | 5.4635 |
TMO
Thermo Fisher Scientific Inc
|
469.21 | 174.37B | 45.20B | 6.88B | 6.75B | 18.19 |
DHR
Danaher Corp
|
175.15 | 123.97B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
567.46 | 45.07B | 4.30B | 1.06B | 1.04B | 13.08 |
A
Agilent Technologies Inc
|
114.52 | 32.36B | 7.07B | 1.29B | 993.00M | 4.5355 |
WAT
Waters Corp
|
307.12 | 30.15B | 3.17B | 642.63M | 516.49M | 10.77 |
Illumina Inc Stock (ILMN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-12-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Jul-11-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Mar-04-25 | Reiterated | Citigroup | Neutral |
| Feb-28-25 | Downgrade | HSBC Securities | Buy → Hold |
| Feb-10-25 | Downgrade | Barclays | Equal Weight → Underweight |
| Feb-07-25 | Downgrade | TD Cowen | Buy → Hold |
| Dec-11-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-12-24 | Resumed | Morgan Stanley | Equal-Weight |
| Oct-17-24 | Upgrade | HSBC Securities | Hold → Buy |
| Aug-28-24 | Upgrade | Argus | Hold → Buy |
| Aug-16-24 | Upgrade | Daiwa Securities | Neutral → Buy |
| Aug-14-24 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-14-24 | Upgrade | TD Cowen | Hold → Buy |
| Jul-10-24 | Upgrade | Citigroup | Neutral → Buy |
| Jun-03-24 | Resumed | Jefferies | Hold |
| Jan-16-24 | Downgrade | HSBC Securities | Buy → Hold |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-18-23 | Upgrade | Scotiabank | Sector Perform → Sector Outperform |
| Dec-15-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-14-23 | Initiated | Stephens | Overweight |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-11-23 | Upgrade | Citigroup | Sell → Neutral |
| Nov-10-23 | Downgrade | Canaccord Genuity | Buy → Hold |
| Sep-28-23 | Initiated | Bernstein | Underperform |
| Jul-05-23 | Resumed | JP Morgan | Neutral |
| Jan-25-23 | Downgrade | Argus | Buy → Hold |
| Jan-05-23 | Initiated | Scotiabank | Sector Perform |
| Dec-12-22 | Downgrade | Citigroup | Neutral → Sell |
| Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
| Oct-04-22 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Sep-28-22 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| Jul-13-22 | Downgrade | Barclays | Equal Weight → Underweight |
| Jan-18-22 | Upgrade | Stifel | Hold → Buy |
| Jan-11-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Jan-07-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-06-22 | Resumed | Piper Sandler | Overweight |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Aug-19-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Jun-01-21 | Upgrade | Evercore ISI | Underperform → In-line |
| Mar-31-21 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Mar-31-21 | Upgrade | Canaccord Genuity | Hold → Buy |
| Mar-03-21 | Initiated | Barclays | Underweight |
| Dec-22-20 | Upgrade | Piper Sandler | Neutral → Overweight |
| Dec-17-20 | Upgrade | BTIG Research | Neutral → Buy |
| Oct-13-20 | Downgrade | Guggenheim | Buy → Neutral |
| Sep-30-20 | Initiated | Atlantic Equities | Overweight |
| Sep-29-20 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Sep-22-20 | Downgrade | Stifel | Buy → Hold |
| Sep-22-20 | Downgrade | UBS | Buy → Neutral |
| Sep-21-20 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-21-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Equal-Weight |
| Aug-07-20 | Downgrade | Evercore ISI | In-line → Underperform |
| Aug-07-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-07-20 | Downgrade | Guggenheim | Buy → Neutral |
| Apr-24-20 | Downgrade | Citigroup | Buy → Neutral |
| Apr-21-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Jan-08-20 | Initiated | Wells Fargo | Underweight |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Jan-02-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-15-19 | Initiated | Stifel | Buy |
| Oct-25-19 | Initiated | Guggenheim | Buy |
View All
Illumina Inc Stock (ILMN) Latest News
Illumina revenue up 4.8% to USD 1.09B in Q1 2026 - Medical Buyer
Jennison Associates LLC Has $26.21 Million Stock Position in Illumina, Inc. $ILMN - MarketBeat
Illumina jumps 7.1% as Q1 results top expectations and full-year outlook rises - Quiver Quantitative
Illumina (NASDAQ:ILMN) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says - MarketBeat
Here’s Why Illumina Stock Could Deliver 8% Annual Returns Through 2028 - TIKR.com
Illumina, Inc. (NASDAQ:ILMN) Q1 2026 Earnings Call Transcript - Insider Monkey
Canaccord cuts Illumina stock price target on competition concerns By Investing.com - Investing.com Canada
Evercore ISI raises Illumina stock price target on strong results By Investing.com - Investing.com Canada
Florida Hospital Association adds Gaye Walker as communications VP - Florida Politics
Illumina (NASDAQ:ILMN) Releases Earnings Results, Beats Estimates By $0.10 EPS - MarketBeat
Illumina (ILMN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo News Malaysia
Illumina Q1 Earnings Call Highlights - Yahoo Finance
Illumina Q1 2026 slides: earnings beat on clinical strength, margins expand - Investing.com India
Illumina (ILMN) Q1 2026 Earnings Transcript - AOL.com
Illumina (ILMN) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance
Illumina (NASDAQ:ILMN) Issues FY 2026 Earnings Guidance - MarketBeat
Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises - Investing.com
Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises By Investing.com - Investing.com Canada
Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026 - TradingView
Illumina lifts 2026 outlook and expands share buybacks - TipRanks
Illumina Q1 Non-GAAP Earnings, Revenue Rise; Raises 2026 Outlook - marketscreener.com
(ILMN) Illumina Expects Fiscal 2026 Adjusted EPS Range $5.15-$5.30, vs. FactSet Est of $5.12 - marketscreener.com
Illumina: Q1 Earnings Snapshot - 10TV
Earnings Flash (ILMN) Illumina, Inc. Reports Q1 Revenue $1.09B, vs. FactSet Est of $1.07B - marketscreener.com
[8-K] ILLUMINA, INC. Reports Material Event - Stock Titan
Illumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR Newswire
Tempus AI vs. Illumina: Which Oncology Stock Is Worth Buying Now? - TradingView
Illumina set to report earnings amid rising Roche competition By Investing.com - Investing.com Australia
Vanguard reports 7.94M shares in Illumina (ILMN) Schedule 13G - Stock Titan
Illumina Inc. Stock (US4523271090): Q1 2026 Earnings Release Expected Today - AD HOC NEWS
Illumina Q1 2026 earnings preview - MSN
Illumina Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Discipline and Rules-Based Execution in ILMN Response - Stock Traders Daily
Illumina (ILMN) Q1 Earnings Report Preview: What To Look For - Yahoo Finance
Will DRAGEN v4.5’s ML-Powered Genomics Upgrade Reshape Illumina’s (ILMN) Precision Medicine Narrative? - Yahoo Finance
Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics - Yahoo Finance
Illumina, Inc. $ILMN Shares Acquired by Keybank National Association OH - MarketBeat
Illumina (ILMN) Q1 earnings report preview: What to look for - MSN
Illumina Inc. stock outperforms competitors despite losses on the day - MarketWatch
Illumina, Inc. Experiences Revision in Its Stock Evaluation Amid Strong Financial Metrics - Markets Mojo
Prenatal Testing Services Market key players 2025-2031 : Illumina Inc, Centogene NV., Revvity, Inc. etc - openPR.com
ILMN Stock Price, Quote & Chart | ILLUMINA INC (NASDAQ:ILMN) - ChartMill
Illumina, Inc. (ILMN) Stock Analysis: Unveiling Growth Potential With A Promising Upside - DirectorsTalk Interviews
Illumina, Inc. $ILMN Shares Sold by KLP Kapitalforvaltning AS - MarketBeat
Illumina unveils roadmap of groundbreaking NovaSeq X advancements in data quality, output, speed, and flexibility - Illumina
Illumina Inc. stock outperforms competitors on strong trading day - MarketWatch
ILMN CLASS ACTION NOTICE: Kessler Topaz Meltzer & Check, LLP Reminds Illumina, Inc. (ILMN) Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors with Substantial Losses to Contact the Firm - TMX Newsfile
Universal Beteiligungs und Servicegesellschaft mbH Sells 15,739 Shares of Illumina, Inc. $ILMN - MarketBeat
Human Microbiome Sequencing Technology Market Competitive - openPR.com
Omics-Based Clinical Trials Research Report 2026: $47.78 Bn Market Opportunities, Trends, Competitive Landscape, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F - GlobeNewswire Inc.
Illumina Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Illumina Inc Stock (ILMN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.37%
0.54%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):